MEG SCHULTE: Open Payments
NPI 1518427640 · BEVERLY HILLS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,214 in 92 payments from 19 companies in 2025. Trend: 2023 $854 · 2024 $1,246 · 2025 $2,214
Food & beverage: $2,214
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 8 | $278 |
| Lundbeck LLC | 9 | $248 |
| Axsome Therapeutics, Inc. | 11 | $243 |
| Otsuka America Pharmaceutical, Inc. | 13 | $239 |
| ABBVIE INC. | 9 | $200 |
| Neurocrine BioSciences, Inc. | 4 | $167 |
| Noven Therapeutics, LLC | 3 | $158 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $149 |
| Corium, LLC | 8 | $137 |
| Collegium Pharmaceutical, Inc. | 4 | $81 |
Products named: REXULTI, Auvelity, VRAYLAR, INGREZZA, ARISTADA, CAPLYTA, Xelstrym, Azstarys.
Industry payments across MI — which companies pay providers there.
